Pengukuran Risiko Gangguan Tidur pada Penggunaan Angiotensin Converting Enzyme Inhibitor dan Calcium Channel Blocker: Case Control Study di Puskesmas Dau, Malang

Sleep disorder or insomnia arisen in hypertensive patients might be derived as a side effect of antihypertensive mediations such as Angiotensin Converting Enzyme Inhibitor (ACEI) and Calcium Channel Blocker (CCB), but the influence of each group had not been much compared. Therefore, a research was conducted using case control design to assess the risk of using ACEI and CCB against the incidence rate of insomnia. Demographic data and insomnia status were collected through Data Collector Sheet and Athens Insomnia Scale (AIS) questionnaire before univariate, bivariate, and multivariate analysis was conducted. The result showed that in the age group of 56–60 years patients undergoing treatment with ACEI have a smaller risk of insomnia of approximately 0.38 times (p=0.026, 95% CI=0.15–0.94) compared to the other patients who were treated with CCB, while in other categorial groups, no significant relationship was found. Thus, the monitoring of insomnia side effects becomes important to be conducted by healthcare professional especially in patients undergoing treatment with CCB at the ages of 56–60 years.